Live tape
Top 8, mentions 7d14,334NVDA4,850 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

MLYS

NASDAQ

Mineralys Therapeutics (MLYS)

27 USD −0.30% vs prior close
Mineralys Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
2.4B USD
EPS, diluted, year to Dec 2025
−2.29 USD
52-week range
12.85 USD – 47.33 USD
Avg volume
337.8K

as of Jul 17, 2026

Have Mineralys Therapeutics (MLYS) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Mineralys Therapeutics insiders reported 5 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026.

Form 4, 90 days to 10 Nov 2026, newest reported trade 30 Sep 2026

0buys
5sells
$5.40Mnet sold
5other filings
Have Mineralys Therapeutics (MLYS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Sep 2026Congleton JonChief Executive OfficerSell75,0001.9M USD
22 Sep 2026Slingsby Brian TaylorDirectorSell104,3203.0M USD
21 Sep 2026Warren EricChief Commercial OfficerSell7,438209K USD
15 Sep 2026Karydas DaphneDirectorSell3,00086K USD
21 Aug 2026Warren EricChief Commercial OfficerSell7,437193K USD
Sold5 open-market sales197,195$5.40M
5 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Mineralys Therapeutics (MLYS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
19 Oct 2026COATS LONNELDirectorAward12,400
19 Oct 2026Peterson KristineDirectorAward12,400
21 Sep 2026Warren EricChief Commercial OfficerOption exercise7,43898K USD
15 Sep 2026Karydas DaphneDirectorOption exercise3,00036K USD
21 Aug 2026Warren EricChief Commercial OfficerOption exercise7,43798K USD

Which funds hold Mineralys Therapeutics (MLYS)?

9 of the 45 institutional funds we track reported a Mineralys Therapeutics position for the quarter ended 30 Jun 2026 — a combined 95.8M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Mineralys Therapeutics (MLYS)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded1,221,75833.0M USD+132.6%
Tudor Investment CorpAdded738,37019.9M USD+374.1%
Citadel AdvisorsHeld (±25%)467,59812.6M USD−22.1%
Renaissance TechnologiesHeld (±25%)378,30010.2M USD−1.2%
D. E. Shaw & Co.Trimmed352,7299.5M USD−60.2%
Two Sigma InvestmentsTrimmed162,0824.4M USD−48.0%
AQR Capital ManagementHeld (±25%)152,5044.1M USD+2.3%
Man GroupAdded59,6401.6M USD+488.2%
Marshall WaceAdded18,000486K USD+100.3%
Point72 Asset ManagementExited

What has been filed or recorded for Mineralys Therapeutics (MLYS)?

The filings we hold for Mineralys Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 02 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Mineralys Therapeutics (MLYS)?
And
02 Oct 2026Fails to deliverShares failed to deliver1,330 shares32K USD notional · 0.002% of shares out
01 Oct 2026Fails to deliverShares failed to deliver10,220 shares257K USD notional · 0.012% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.64 USD
30 Sep 2026FinancialsTotal assets630.1M USDat period end
30 Sep 2026FinancialsTotal equity503.8M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −2.85 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.47 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.29 USD
31 Dec 2025FinancialsNet income−154.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.29 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.52 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.66 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.79 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −3.66 USD

What do people ask about Mineralys Therapeutics (MLYS)?

From live data
What is Mineralys Therapeutics’ market cap?2.4B

Mineralys Therapeutics is worth 2.4B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Mineralys Therapeutics insiders bought or sold shares recently?5 sales

In the 90 days to 10 Nov 2026, Mineralys Therapeutics insiders reported 5 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Mineralys Therapeutics?9 of 45

9 of the 45 funds we track reported a Mineralys Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Tudor Investment Corp and Citadel Advisors. See Funds

When did Mineralys Therapeutics last report earnings?−0.64

Mineralys Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.64 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings